All:
Haven't looked beyond the abstract and a glance at the money-shot Figure and table yet:
PLoS One. 2017 Dec 6;12(12):e0186459. doi: 10.1371/journal.pone.0186459. eCollection 2017.
An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers.
Airhart SE1, Shireman LM2, Risler LJ2, Anderson GD3, Nagana Gowda GA4,5, Raftery D4,5, Tian R5, Shen DD2,3, O'Brien KD1.
... In this non-randomized, open-label PK study of 8 healthy volunteers, 250 mg NR was orally administered on Days 1 and 2, then uptitrated to peak dose of 1000 mg twice daily on Days 7 and 8. On the morning of Day 9, subjects completed a 24-hour PK study after receiving 1000 mg NR at t = 0. Whole-blood levels of NR, clinical blood chemistry, and NAD+ levels were analyzed.
RESULTS:
Oral NR was well tolerated with no adverse events. Significant increases comparing baseline to mean concentrations at steady state (Cave,ss) were observed for both NR (p = 0.03) and NAD+ (p = 0.001); the latter increased by 100%. Absolute changes from baseline to Day 9 in NR and NAD+ levels correlated highly (R2 = 0.72, p = 0.008). ...
PMID: 29211728
DOI: 10.1371/journal.pone.0186459
This constitutes the publication of this trial registered at clinicaltrials.gov .